郑毅然

发布者：金雪明发布时间：2020-03-11浏览次数：22924




姓       名：郑毅然
职务荣誉：特聘教授, 博士生导师
                国家级青年人才计划获得者
                江苏省双创人才
                姑苏创新创业领军人才
电子邮箱：yrzheng@suda.edu.cn
办公地址：苏州大学独墅湖校区二期药学院云轩楼1429

教育经历：

2006.09 – 2009.05: 美国约翰·霍普金斯大学 (JHU)，学士

2010.09 – 2015.11: 美国麻省理工学院 (MIT)，生物工程，博士

2017.08 – 2019.07: 新加坡国立大学 (NUS)，商务分析（医疗卫生），在职MSBA


科研工作经历：

在新加坡科技研究局（A*STAR）任博士后和科研员，从事生物工程研究，后加盟苏州大学药学院。多年来结合免疫学、材料工程、合成生物学和生物科技研发了新型CAR-T细胞疗法、癌症疫苗和其智能武装体系，以通讯/第一作者在Nat Biotechnol、Adv Mater、ACS Nano、Adv Funct Mater、J Control Release等期刊发表研究论文。相关技术已申请17项国际、国内发明专利，转让3项，基于相关技术的公司产品在美国开展临床试验。郑博士主持国家自然科学基金和国家生物药技术创新中心细胞疗法“揭榜挂帅”技术攻关项目等，担任中国抗癌协会纳米肿瘤学专业委员会委员、中国颗粒学会理事会青年理事，Adv Mater、Adv Sci等十多本期刊审稿人。


研究方向：

细胞治疗、疫苗、智能响应性药物递送系统、免疫工程、生物材料


代表性论文：

  1. M. Gao#, Y. Liu#, L. Zhao#, J. Chen, W. Wan, Z. Yuan, L. Li, Y. Huang, Y. Wang*,Y. Zheng*, Cell Surface-tethered Nucleic Acid Therapeutics Program Robust and Tumor-responsive Enhancement of Adoptive Cell Therapy,Advanced Materials, DOI: 10.1002/adma.202419969 (2025).

  2. P. Zhang#, G. Cui#, T. Wang, X. Zhao, X. Wang, R. Ye, T. Liu*,Y. Zheng*, Z. Zhong*, In situ therapeutic vaccines for leukemia by chemo-nanoadjuvant therapy,Journal of Controlled Release, DOI:10.1016/j.jconrel.2025.113851 (2025).

  3. P. Zhang#, T. Wang#, G. Cui#, R. Ye, W. Wan, T. Liu*,Y. Zheng*, Z. Zhong*. Systemic multifunctional nanovaccines for potent personalized immunotherapy of acute myeloid leukemia,Advanced Materials, 36,2407189 (2024).

  4. W. Wan#, W. Han#, J. Chen, Y. Li, L. Zhao, M. Gao, C. Shen, N. Liu, W. Deng, S. Ma, L. Cheng,Y. Zheng*. Chemokine-based injectable navigation system for enhancing CAR-T cell therapy against solid tumors.Advanced Functional Materials, 34, 2401161 (2024).封面文章

  5. W. Deng#, J. Chen#, X. Wang#, Q. Wang, L. Zhao, Y. Zhu, J. Yan*,Y. Zheng*. Paravertebrally‐injected multifunctional hydrogel for sustained anti‐inflammation and pain relief in lumbar disc herniation.Advanced Healthcare Materials, 13, 2401227 (2024).

  6. G. Cui, Y Sun, L. Qu, C. Shen, Y. Sun, F. Meng,Y. Zheng*, Z. Zhong*. Uplifting anti-tumor immunotherapy with lymph node-targeted and ratio-controlled co-delivery of tumor cell lysate and adjuvant.Advanced Healthcare Materials, 13, 2303690 (2024).

  7. X. Chen, M. Gao, S. An, L. Zhao, W. Han, W. Wan, J. Chen, S. Ma, W. Cai, Y. Cao, D. Ding, Y. Y. Yang, L. Cheng*,Y. Zheng*. Enhancing adoptive T cell therapy for solid tumor with cell-surface anchored immune checkpoint Inhibitor nanogels.Nanomedicine:NBM, 45,102591 (2022).

  8. Y. Zheng*, Z. Zhong*. Roadmap to next-generation cancer vaccines.Journal of Controlled Release, 347, 308-313 (2022).封面文章

  9. J. Yan#, X. Liu#, F. Wu, C. Ge, H. Ye, X. Chen, Y. Wei, R. Zhou, S. Duan, R. Zhu,Y. Zheng, L. Yin*. Platelet pharmacytes for the hierarchical amplification of antitumor immunity in response to self-generated immune signals.Advanced Materials, 34, 2109517 (2022).

  10. M. Hou, Y. Wei, Z. Zhao, W. Han, R. Zhou, Y. Zhou,Y. Zheng, L. Yin*. Immuno-engineered nanodecoys for the multi-target anti-inflammatory treatment of autoimmune diseases.Advanced Materials, 32, 2108817 (2022).

  11. M. He#, T. Yang#, Y. Wang, M. Wang, X. Chen, D. Ding*,Y. Zheng*, H. Chen*. Immune Checkpoint Inhibitor‐Based Strategies for Synergistic Cancer Therapy.Advanced Healthcare Materials, 10, 2002104 (2021).

  12. Y. Zheng*, J. Kng, C. Yang, J. L. Hedrick, Y. Y. Yang*. Cationic polymer synergizing with chemotherapeutics and re-purposing antibiotics against cancer cells.Biomaterials Science, 9, 2174-2182 (2021).

  13. L. Tang#*,Y. Zheng#, M. Melo, L. Mabardi, A. P. Castano, Y.Q. Xie, N. Li, S. B. Kudchodkar, H. C. Wong, E. K. Jeng, M. V. Maus, and D. Irvine*. Enhancing T-cell therapy through TCR signaling-responsive nanoparticle drug delivery.Nature Biotechnology,36 (8), 707 (2018).封面文章，同刊评述 “A backpack revs up T-cell activity” by Shum, Heslop

  14. Y. Zheng, L. Tang, L. Mabardi, S. Kumari and D. Irvine. Enhancing adoptive cell therapy of cancer through targeted delivery of small-molecule immunomodulators to internalizing or non-internalizing receptors.ACS Nano, 11(3):3089-3100 (2017).

  15. Y. Zheng, M. T. Stephan, S. A. Gai, W. Abraham, A. Shearer, and D. J. Irvine.In vivo Targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes.Journal of Controlled Release,172(2):426-35 (2013).

  16. H. Liu, K. Moynihan,Y. Zheng, G. Szeto, A. Li, B. Huang, D. Egeren, C. Park, D.Irvine.  Structure-based programming of lymph-node targeting in molecular vaccines.Nature, 507(7493): 519–522 (2014).



主要荣誉：

2019/2020：国家海外高层次人才；江苏省双创人才；姑苏创新领军人才；金鸡湖高层次人才

2006-2015：全额奖学金在美国约翰·霍普金斯大学和麻省理工学院学习